Abstract:Weijian Zhu, 1 Ying He, 1 Mufang Huang, 1 Shezhu Fu, 1 Ziyi Liu, 1 Xiaoqi Wang, 1 Zhixin Li, 1 Xiaoliang Li, 1 Jiangming Chen, 2 Yangqiu Li 3 1 Department of Hematology, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital), Zhuahai, 519050, People's Republic of China; 2 Department of Haematology, Wuzhou Gongren Hospital, Wuzhou, 543001, People's Republic of China; 3 Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 10632, People's Republic of China Correspondence: Yangqiu Li, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, People's Republic of China, Email Objective: We evaluated the long-term safety and efficacy of thalidomide in the treatment of transfusion-dependent β-thalassemia (TDT). Methods: Fifty patients with TDT were treated with thalidomide and followed-up for 5 years. Thalidomide at a 50 mg dose was administered once a day after dinner. The dose was increased to 150 mg/d after 3 d if well tolerated. After 1 year of treatment, the hemoglobin (Hb) level was stabilized at its maximum, and thalidomide was gradually reduced and maintained at the minimum dose. The hematological response, transfusion dependence, and haemolytic indicators were assessed. Results: At 9 month of follow-up, 38 (76%) patients achieved an excellent response, 1 (2%) a good response, 4(8%) a minor response, and 7(14%) did not show a response. The overall response rate was 86%. At 9 months, the Hb level increased from 79.0 ± 13.2 g/L at baseline to 99.0 ± 13.7g/L ( P < 0.001). Patients who achieved excellent response continued to show an increase in Hb levels during follow-up. At 48 months, the mean Hb level was 98.99 ± 10.3g/L; 21 patients (84.0%) became transfusion independent. Thalidomide was reduced and maintained to 25 mg/d in three of these patients. Moreover, five patients completed 60 months of follow-up, and with a mean Hb level of 99.8 ± 6.7g/L. During follow-up, grade 1– 2 adverse drug reactions were noted; however, no grade 3 or higher adverse event was reported. However, no decrease in hemolytic indicators was observed. Conclusion: Thalidomide was well tolerated in the long term, while it significantly improved Hb levels and reduced the transfusion burden. Keywords: β-thalassemia, transfusion-dependent, thalassemia, thalidomide, foetal hemoglobin Beta-thalassemia is one of the most common single gene inherited diseases. The World Health Organization reported that approximately 150 million people worldwide carry the hemoglobinopathy gene, representing a substantial global health burden. The incidence of hemolytic anemia is mainly concentrated in tropical and subtropical areas, primarily on the Mediterranean coast, African America, North Africa, Southeast Asia, the Indian subcontinent, and Melanesia in the Pacific Islands. 1 In these areas, the high incidence of hemolytic anemia caused by hemoglobinopathies is a serious public health problem. 2,3 Beta-thalassemia is mainly caused by point mutation of the β-globin gene or loss or insertion of individual nucleotides. This results in accumulation of excess, unbound α-globin chains that precipitate in erythroid precursors in the bone marrow and mature erythrocytes, leading to ineffective erythropoiesis and peripheral hemolysis. 4 Beta-thalassemia was classified clinically as transfusion dependent or non-transfusion dependent. 5 Patients with transfusion-dependent β-thalassemia need regular red blood cell transfusions and iron chelation therapy to long-term survival; however, blood transfusion is associated with iron overload, which causes end-organ damage, thus, increasing morbidity and mortality. Currently, curative options for these diseases include allogeneic bone marrow transplantation and gene therapy or gene editing; 6–8 however these methods are costly, and safety challenges limit their use worldwide, especially in developing countries. Fetal hemoglobin (HbF) inducers activate γ-globin genes that are largely turned off in patients with β-thalassaemia. The synthesized γ-chain can replace the defective β-chain, and the HbF formed by the relative excess of α-chain can be compensated by an increase in the production of the β-like globin molecule, the γ-globin. Reducing the number of unbound α-globin chains in red blood cells may ameliorate its detrimental effects and increase total (Hb) levels. 9 Hydroxyurea is the most widely use HbF inducer used in sickle cell disease; however, it is less effective for patients with β-thalassemia. 10 Other inducers such as 5-azacytidine and decitabine have no -Abstract Truncated-

Macitentan Administration for Pulmonary Hypertension Due to β-thalassemia with Multiple Organ Failure

The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience

Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension.

A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial

Real-world effectiveness and safety of macitentan in patients with pulmonary artery hypertension: a multicenter, retrospective, observational study in China

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Proteomic Analysis of Macitentan on Hypoxic Rat Lungs Reveals New Targets for Pulmonary Hypertension Treatment

Efficacy and safety of macitentan in Fontan-palliated patients: 52-week randomized, placebo-controlled RUBATO phase 3 trial and open-label extension

Case Report: Apatinib Plus Selexipag As a Novel Therapy for Pulmonary Tumor Thrombotic Microangiopathy Accompanied by Pulmonary Hypertension Associated with Gastric Carcinoma.

SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation

Successful treatment of persistent pulmonary hypertension of the newborn with bosentan

Survival and complication rates in patients with thalassemia major in Taiwan

Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators

Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation

Outcome of Oral Bosentan in Children with Congenital Heart Disease Associated Pulmonary Arterial Hypertension

A Case of Mixed Connective Tissue Disease Complicated by Pulmonary Hypertension and Ascites After Addition of Pulmonary Vasodilators.

Long-Term Follow-Up of Patients Undergoing Thalidomide Therapy for Transfusion-Dependent β-Thalassaemia: A Single-Center Experience

Clinical use of macitentan in the treatment of connective tissue disease-associated pulmonary arterial hypertension

PSUN160 Transfusion Related Endocrinopathies and Thalassemia (TREAT) Study

Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report